Encontrados 20 documentos, a visualizar página 1 de 2

Hepcidin serum levels and resistance to recombinant human erythropoietin therap...

This title was also presented orally at Clinical Biochemistry workshop,Faro, 29 Janeiro, 2010

Resistance to recombinant human erythropoietin therapy in haemodialysis patients

To better clarify the mechanism of resistance to recombinan thuman erythropoietin (rhEPO) therapy in haemodialysis patients, we studied systemic changes associated with resistance to rhEPO therapy in haemodialysis patients under rhEPO therapies, with particular interest on inflammation, leukocyte activation, iron status, oxidative stress and erythrocyte damage. We studied 63 chronic kidney disease (CKD) patient...

Inflammation, T-Cell phenotype, and inflammatory cytokines in chronic kidney di...

Background Resistance to recombinant human erythropoietin (rhEPO) occurs in some chronic kidney disease (CKD) patients, which may be due to enhanced systemic inflammatory response and to the erythropoiesis-suppressing effect of pro-inflammatory cytokines, some of which are produced by T cells. Aim of study The aim of this study was to investigate the relationship between resistance to rhEPO therapy in hemodialy...

Higher fibrinolytic and inflammatory markers are associated with central venous...

T-cell phenotype and inflammation in chronic kidney disease patients under haem...

IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to r...

Neutrophil activation and resistance to recombinant human erythropoietin therap...

The aim of this work was to evaluate the neutrophil activation state in chronic kidney disease (CKD) patients under hemodialysis, and its linkage with resistance to recombinant human erythropoietin (rhEPO) therapy. Methods: We studied 63 CKD patients under hemodialysis and rhEPO treatment (32 responders and 31 non-responders to rhEPO therapy). In 20 of the CKD patients (10 responders and 10 non-responders to rh...

DMT1 (NRAMP2/DCT1) genetic variability and resistance to recombinant human eryt...

Band 3 profile as a marker of erythrocyte changes in chronic kidney disease pat...

Our aim was to study changes in red blood cell (RBC) membrane band 3 profile, as a cumulative marker of RBC changes, in chronic kidney disease (CKD) patients under haemodialysis and recombinant human erythropoietin (rhEPO) therapy and its linkage with resistance to this therapy. We studied 63 CKD patients, 32 responders and 31 non-responders to rhEPO therapy, and 26 healthy individuals. We evaluated the band 3 ...

Changes in red blood cells membrane protein composition during hemodialysis pro...

Our aim was to evaluate the influence of the hemodialysis (HD) procedure in red blood cells (RBC) membrane protein composition. We evaluated hematological data (RBC count, hemoglobin concentration, and hematimetric indices) and RBC membrane protein composition (linear and exponential gradient polyacrylamide gel electrophoresis in the presence of sodium dodecylsulfate [SDS-PAGE] followed by densitometry analysis...